Latest news with #F.Hoffmann-LaRocheAG
Yahoo
27-02-2025
- Health
- Yahoo
Fetus Receives Life-Saving Medication Inside Womb in Medical First
Doctors in the US have treated a fetus with a rapidly progressive congenital disease from inside the womb for the very first time. Instead of giving medicine to a child with severe neuromuscular complications after they are born, a new case study details how a prospective mother agreed to take the medicine for her developing fetus while she was still pregnant. A prenatal test had shown that her fetus held two genetic mutations indicating type 1 spinal muscular atrophy (SMA), which usually results in severe muscle weakness and breathing difficulties within six months of birth. Historically, most children with type 1 SMA die by their second birthday, usually from respiratory failure. However, the child in this study has so far made it to the age of two and a half years with no sign of symptoms. The parents of the treated child had previously experienced the loss of their baby to spinal muscular atrophy, and when testing showed their most recent fetus also had the progressive neuromuscular disease, they wanted to know if they could start treatments earlier. For this single case, the FDA approved the early administration of the oral drug risdiplam, brand name Evrysdi, owned by the pharmaceutical company F. Hoffmann-La Roche AG. Over the years, randomized controlled trials have shown risdiplam to be both safe and effective at treating spinal muscular atrophy in newborns, and the younger the kids are when they start receiving the medicine, the better the outcomes overall. In the new study, the pregnant mother took a dose of risdiplam each day for six weeks before giving birth. Testing found that the medicine trickled right through her umbilical cord blood and the amniotic fluid bathing her fetus. After birth, it was the infant that was given the daily oral drug, not the mother. Pediatric neurologist Michelle Farrar, who is working on a minimally invasive gene therapy treatment for SMA in Australia, told Smriti Mallapaty at Nature that the baby girl with SMA "has been effectively treated, with no manifestations of the condition" even 30 months after birth. In 2020, risdiplam was first approved by the US Food and Drug Administration (FDA) for kids with spinal muscular atrophy, but only over the age of two months. Recent clinical trials funded by Roche, however, found the majority of children with spinal muscular atrophy treated with risdiplam before six weeks of age could swallow, feed, sit, stand, and walk on their own after two years of treatment. None required permanent ventilation. Risdiplam works to prevent the degeneration of nerve cells in the brain and body by increasing the concentration of a crucial protein, called survival motor neuron (SMN) protein. Active SMN proteins are lacking in those with genetic mutations that cause spinal muscular atrophy. "In children with SMA, motor neuron degeneration starts before the onset of symptoms, so time is of the essence if we hope to preserve muscle function," said pediatric neurologist Laurent Servais in a press release for a Roche clinical trial in 2024. "It's heartening to see that through early intervention with Evrysdi these children have achieved important milestones like sitting, standing, and walking that would typically be unattainable without treatment." Whether or not the recent case study in the US will inspire and embolden doctors and parents to trial risdiplam at earlier stages of development remains to be seen. "Results in this single case cannot be generalized but may support the consideration of prenatal risdiplam treatment for SMA identified in utero," write the authors of the correspondence. The study was published in The New England Journal of Medicine. There's a Critical Thing We Can All Do to Keep Alzheimer's Symptoms at Bay Traces of a Nutrient in Brazil Nuts Could Fight Cancer, But Dosage Is Crucial Tardigrade Protein Could Soon Make Cancer Patients More Radiation Proof
Globe and Mail
18-02-2025
- Business
- Globe and Mail
Immunohistochemistry Market: Latest Trends, Technological Advancements, Driving Factors, and Forecast until 2029
"F. Hoffmann-La Roche AG (Switzerland) stands out as a major player in the global immunohistochemistry (IHC) market. Operating through its Pathology Lab segment within the Diagnostics Division, Roche provides a comprehensive range of IHC products, including the BenchMark ULTRA IHC/ISH System and the OptiView DAB IHC Detection Kit." The global immunohistochemistry market, valued at US$3.4B in 2023, is forecasted to grow at a 7.2% CAGR, reaching US$3.7B by 2024 and US$5.2B by 2029. The global Immunohistochemistry Market is valued at an estimated USD 3.4 billion in 2024 and is projected to reach USD 5.2 billion by 2029 at a CAGR of 7.2% during the forecast period. The global Immunohistochemistry (IHC) market is driven by the rising incidence of cancer, which increases the demand for accurate diagnostic tools like IHC tests. Innovations in antibodies and automated equipment have improved the accuracy and efficiency of cancer detection, while the growing adoption of personalized treatment plans presents significant opportunities. However, alternative technologies such as in situ hybridization, NGS, and RNA sequencing pose challenges to IHC market growth. The rise of digital pathology, offering benefits like reduced turnaround times and improved workflow, further supports market expansion. Nevertheless, the lack of standardization in IHC products limits growth, though ongoing efforts to address this issue are underway. Companion diagnostics, which tailor treatments to individual patients, also present opportunities for market growth. Despite competition from alternative methods, the IHC market continues to grow, with significant contributions from major players like F. Hoffmann-La Roche, Danaher Corporation, and Agilent Technologies. The diagnostic applications segment holds the largest market share, driven by the increasing need for accurate disease diagnosis, while antibodies remain the most significant product segment. Hospitals and diagnostic laboratories are the primary end users, with North America experiencing notable growth due to advanced diagnostic infrastructure and high disease prevalence. Download PDF Brochure: Browse in-depth TOC on " Immunohistochemistry Market" 666 - Tables 63 - Figures 489 - Pages F. Hoffmann-La Roche AG: Leading Innovator in Immunohistochemistry F. Hoffmann-La Roche AG (Switzerland) stands out as a major player in the global immunohistochemistry (IHC) market. Operating through its Pathology Lab segment within the Diagnostics Division, Roche provides a comprehensive range of IHC products, including the BenchMark ULTRA IHC/ISH System and the OptiView DAB IHC Detection Kit. The company has reinforced its market position with the launch of new and improved products, such as the BenchMark ULTRA PLUS system, the VENTANA DP 600 slide scanner, the Elecsys anti-p53 Immunoassay, and the VENTANA ALK (D5F3) CDx Assay. Roche's global reach spans Europe, the Middle East & Africa, North America, Asia Pacific, and Latin America. Danaher Corporation: Pioneering Solutions in Immunohistochemistry Danaher Corporation (US) excels in the IHC market through its subsidiary Leica Biosystems. This division, part of the Anatomical Pathology Diagnostics and Core Lab Diagnostics segments, offers a wide array of chemical and immuno-staining instruments, reagents, and consumables. Danaher's market leadership is attributed to its extensive customer base, advanced technology, significant R&D investments—amounting to USD 1.50 billion in 2023—and collaborations with research institutions and clinicians worldwide. Notable developments include a partnership with Navinci for advanced cancer research and the acquisition of Cell IDx, Inc., enhancing Danaher's competitive edge in the IHC market. Agilent Technologies, Inc.: Key Contributor to IHC Diagnostics Agilent Technologies, Inc. (US) is a significant player in the IHC market, focusing on cancer diagnostics and anatomic pathology workflows through its Pathology Solutions segment. The company expanded its offerings with partnerships like the one with Incyte for companion diagnostic solutions and with Akoya Biosciences for chromogenic and immunofluorescent multiplex assays. Agilent is also broadening its global footprint with a new Center for Excellence in India and maintains a strong presence in regions including the US, UK, Australia, China, Germany, and Japan, among others. Request Sample Pages: Product Segment: Antibodies Drive Immunohistochemistry Market Growth The immunohistochemistry (IHC) market is categorized into antibodies, reagents, equipment, and kits. In 2023, antibodies dominated the market, driven by advancements in immunohistochemistry that boost R&D activities for various antibodies. The high demand for primary antibodies, which are essential for IHC protocols and widely used in diagnostic and research applications, supports this segment. Additionally, the growth is fueled by increasing adoption of targeted immunotherapy, heightened awareness of healthcare diagnostics, rising approval rates for therapeutic antibodies, and increased R&D spending by pharmaceutical and biotechnology companies. Application Segment: Research Applications Contribute Significantly The IHC market is segmented by application into diagnostic, research, and forensic uses. The research application segment held the second-largest share in 2023. High-throughput automated IHC platforms are utilized in research to ensure consistent staining across slides, crucial for studying drug effects on tissues at the molecular level. IHC products are also vital for identifying drug-induced toxic effects and studying embryonic development, including stem cell differentiation. These factors make IHC techniques essential in developmental studies, stem cell research, and drug testing, thereby contributing to the segment's significant market share. End-User Segment: Academic and Contract Research Organizations Lead The IHC market is divided by end users into hospitals & diagnostic laboratories, academic & contract research organizations (CROs), and other entities such as pharmaceutical & biotechnology companies and forensic laboratories. In 2023, academic & CROs represented the second-largest segment. IHC techniques are extensively used for identifying and validating pharmaceutical targets, analyzing tumor-stroma-immune cell interactions, and categorizing patients in clinical trials. The growing demand for personalized cancer treatments, increased application of IHC in drug development, and rising investments in life sciences research drive this segment's expansion. Regional Insights: North America Dominates the Market The IHC market is segmented by region into North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa. North America led the market in 2023, supported by ongoing economic development, rising healthcare expenditure, and improved access to advanced cancer screening technologies. The region benefits from favorable reimbursement policies for pathology diagnostic tests and high-quality healthcare infrastructure, which further drives the growth of the IHC market.
